Aptcash Enterprises
Parel, Mumbai, Maharashtra
GST No. 27BDTPM3418D1ZF
TrustSEAL Verified
View Mobile No.
SEND EMAIL

Anti Cancer Medicines

Our product range includes a wide range of dasatinib invista 50mg, 100mg, 70mg, dasatinib dasashil 50 mg, 100mg, 70mg and entecavir tablet.

Dasatinib Invista 50mg, 100mg, 70mg

Dasatinib Invista 50mg, 100mg, 70mg
  • Dasatinib Invista 50mg, 100mg, 70mg
  • Dasatinib Invista 50mg, 100mg, 70mg
  • Dasatinib Invista 50mg, 100mg, 70mg
  • Dasatinib Invista 50mg, 100mg, 70mg
Get Best Quote
Approx. Price: Rs 200 / PieceGet Latest Price

Product Details:

Packaging Size50mg,100mg,70mg 3X10 tab box
BrandInvista
CompositionDasatinib
ManufacturerDr Reddy
Treatmentchronic myelogenous leukemia and acute lymphoblastic leukemia. Specifically it is used to treat case
FormTablet
Therapeutic Useschronic myelogenous leukemia and acute lymphoblastic leukemia. Specifically it is used to treat case
Side Effectinfection,suppression of the bone marrow (decreasing numbers of blood cells),headache,hemorrhage
Pregnancy & breast feedingpregnancy may result in harm to the baby
Strength50mg,70mg,100mg

Dasatinib, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+).It is taken by mouth.

Common side effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea.Severe side effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome.Use during pregnancy may result in harm to the baby.It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.

Medical uses
Dasatinib is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive for the Philadelphia chromosome.

In the EU dasatinib is indicated for children with

    newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.
    newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.
    newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

and adults with

    newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;
    chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;
    Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Adverse effects

The most common side effects are infection, suppression of the bone marrow (decreasing numbers of blood cells), headache, hemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnea (difficulty breathing), diarrhea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever.

Neutropenia and myelosuppression were common toxic effects. Fifteen people (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which was a suspected side effect of dasatinib. Some of these people required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of people developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in people treated with dasatinib.

On October 11, 2011, the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH).Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment. Information about the risk was added to the Warnings and Precautions section of the Sprycel drug label.

Pharmacology
Crystal structure(PDB 2GQG) of Abl kinase domain (blue) in complex with dasatinib (red).

Dasatinib is an ATP-competitive protein tyrosine kinase inhibitor. The main targets of dasatinib are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other tyrosine kinases.
Request
Callback


Additional Information:

  • Packaging Details: 50mg, 70mg,100mg 3x10 tab box
Yes! I am Interested

Dasatinib Dasashil 50 Mg, 100mg, 70mg

Dasatinib Dasashil 50 Mg, 100mg, 70mg
  • Dasatinib Dasashil 50 Mg, 100mg, 70mg
  • Dasatinib Dasashil 50 Mg, 100mg, 70mg
  • Dasatinib Dasashil 50 Mg, 100mg, 70mg
  • Dasatinib Dasashil 50 Mg, 100mg, 70mg
Get Best Quote
Approx. Price: Rs 2,000 / PieceGet Latest Price

Product Details:

Packaging Size50mg,70mg 60tab bottle 100mg
BrandDasashil
CompositionDasatinib
ManufacturerShilpa
Treatmentchronic myelogenous leukemia (CML)& acute lymphoblastic leukemia (ALL).Philadelphia chromosome-+ve
Dose Strength50mg,70mg
CategoryBlood Cancer
Drugdasatinib
Generic NameDasatinib
FormTablet
Therapeutic Useschronic myelogenous leukemia (CML)& acute lymphoblastic leukemia (ALL).Philadelphia chromosome-+ve
Side Effectlow white blood cells,low blood platelets,anemia,swelling,rash,and diarrhea.Severe side effects
Strength50mg,70mg,100mg
Quantity Per Pack50mg,70mg,60tab per bottle 100mg 30tab

Dasatinib, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+).It is taken by mouth.

Common side effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea.Severe side effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome.Use during pregnancy may result in harm to the baby.It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.

Medical uses
Dasatinib is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive for the Philadelphia chromosome.

In the EU dasatinib is indicated for children with

    newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.
    newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.
    newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

and adults with

    newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;
    chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;
    Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Adverse effects

The most common side effects are infection, suppression of the bone marrow (decreasing numbers of blood cells), headache, hemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnea (difficulty breathing), diarrhea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever.

Neutropenia and myelosuppression were common toxic effects. Fifteen people (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which was a suspected side effect of dasatinib. Some of these people required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of people developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in people treated with dasatinib.

On October 11, 2011, the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH).Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment. Information about the risk was added to the Warnings and Precautions section of the Sprycel drug label.

Pharmacology
Crystal structure(PDB 2GQG) of Abl kinase domain (blue) in complex with dasatinib (red).

Dasatinib is an ATP-competitive protein tyrosine kinase inhibitor. The main targets of dasatinib are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other tyrosine kinases.
Request
Callback


Additional Information:

  • Packaging Details: 50mg, 70mg tablet (60tab ) Bottle 100mg 30tab bottle
Yes! I am Interested

Entecavir Tablet

Entecavir Tablet
  • Entecavir Tablet
Get Best Quote
Approx. Price: Rs 10 / PieceGet Latest Price

Product Details:

Minimum Order Quantity10 Piece
Strength0.5 mg
ManufacturerZydus
Prescription/Non prescriptionPrescription
Dose/Strength (e.g. 1 mg )0.5 mg,1 mg
Packaging Size1x10
Packaging TypeTablet

Request
Callback
Yes! I am Interested
X

Explore More Product



Reach Us
Aptcash Enterprises (Proprietor)
Aptcash Enterprises
Shop No. 7, B Wing, Nirmala Niwas, Aai Mai Merwanji Road
Parel, Mumbai - 400012, Maharashtra, India


Call Us
View Mobile No.


Send E-mailSend SMS